StockNews.AI

Medicus Pharma Ltd. Studies Demonstrate Long-Acting Therapeutic Approach with Stable Bone Turnover in Women

StockNews.AI • 1 minute

CVSAMGNBMY
High Materiality8/10

Information

PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the...

Original source

AI Summary

Medicus Pharma's Teverelix has demonstrated promising Phase I results, leading to an upcoming presentation at the AACE 2026. The findings support their plan to explore its use in women’s health and could enhance investor interest as the company aims for strategic partnerships and further clinical studies.

Sentiment Rationale

Teverelix's promising Phase I results and strategic plans enhance valuation potential, akin to past biotech success stories.

Trading Thesis

MDCX is likely to see stock appreciation through mid-2026 as clinical developments progress.

Market-Moving

  • Positive Phase I data could lead to increased investor interest and stock price surge.
  • Plans for endometriosis indication may unlock a significant new market for Teverelix.
  • Upcoming Phase 2 data for SkinJect™ could catalyze stock volatility.
  • New partnerships could positively influence investor sentiment towards enhanced valuation.

Key Facts

  • Medicus Pharma's Teverelix Phase I results accepted for AACE presentation.
  • Teverelix shows rapid, reversible hormone suppression with stable bone markers.
  • Company plans to advance Teverelix into endometriosis treatments.
  • SkinJect™ Phase 2 program data expected in Q1 2026.
  • Strategic partnerships aimed for late-stage drug development.

Companies Mentioned

  • Medicus Pharma Ltd. (MDCX): Focuses on Teverelix and SkinJect™ promising developments attract investors.
  • Helix Nanotechnologies, Inc. (Not listed): Non-binding agreement for AI analytics may enhance Medicus's clinical capabilities.
  • SkinJect Inc. (Not listed): Wholly owned Medicus subsidiary poised for significant clinical readouts in 2026.

Corporate Developments

The category is 'Corporate Developments' as Medicus is focusing on multiple promising clinical candidates and strategic partnerships. This positioning potentially enhances its market evaluation and attractiveness to investors.

Medicus Pharma Ltd. to Present Promising Data on Teverelix at AACE Annual Meeting 2026

PHILADELPHIA, Jan. 12, 2026 (GLOBE NEWSWIRE) — Medicus Pharma Ltd. (NASDAQ: MDCX), a precision-guided biotech company, is set to present significant findings on its product, Teverelix, at the American Association of Clinical Endocrinology (AACE) Annual Meeting, scheduled for April 22–24, 2026, in Las Vegas, Nevada. This presentation will shed light on the long-acting gonadotropin-releasing hormone (GnRH) antagonist's effects on bone turnover in healthy female volunteers.

Clinical Findings from Phase 1 Studies

The abstract titled "Evaluation of Teverelix, a Long-Acting GnRH Antagonist: Pharmacokinetics, Pharmacodynamics, Bone Turnover and Safety in Two Phase 1 Studies in Healthy Female Volunteers" contains results derived from two randomized, placebo-controlled Phase I clinical studies involving 48 premenopausal women.

These studies aimed to assess:

  • Absorption rates of Teverelix
  • Suppression of reproductive hormones
  • Effects on bone turnover markers
  • Overall safety following single subcutaneous injections

Key Highlights of Teverelix's Phase 1 Results

The findings from both studies yielded several noteworthy results:

  • Rapid suppression of LH and FSH within 24 hours of dosing.
  • Reversible estradiol suppression, with numerous participants achieving levels between 30–50 pg/mL, mitigating bone loss risks.
  • Sustained hormone suppression lasting up to two to three weeks post-injection at higher dosages.
  • Stable bone turnover markers indicating no short-term evidence of bone loss.
  • A favorable safety profile, with no serious drug-related adverse events.

Expert Insights on Teverelix

Dr. Raza Bokhari, Executive Chairman and CEO of Medicus, remarked: “We believe that these findings reinforce the versatility of Teverelix as a long-acting GnRH antagonist platform. The results support its advancement in treating women’s health conditions such as endometriosis, affecting approximately 10% of women of reproductive age worldwide.”

He added, “We are currently planning a Phase 2 genomics-informed study of Teverelix in women with symptomatic endometriosis, scheduled to take place in the United Arab Emirates (UAE).”

Understanding Teverelix's Mechanism

Teverelix trifluoroacetate is an innovative long-acting injectable GnRH antagonist designed to offer immediate suppression of LH, FSH, and downstream sex hormones without causing an initial hormonal surge. This mechanism is particularly relevant for patients with advanced prostate cancer who are at heightened cardiovascular risk.

Strategic Development and Future Plans

Medicus Pharma Ltd. is focused on advancing select programs through Phase 2 proof-of-concept studies while seeking strategic partnerships for late-stage development and commercialization. The ongoing efforts include:

  • Completing decision-grade clinical and regulatory data packages.
  • Advancing the SkinJect™ Program for the treatment of basal cell carcinoma (BCC).

In addition to Teverelix, the company expects to share topline data from SkinJect™ in Q1 2026.

About Medicus Pharma Ltd.

Medicus Pharma Ltd. (Nasdaq: MDCX) is dedicated to accelerating the clinical development of novel therapeutics and is involved in projects across multiple countries. Its subsidiary, SkinJect Inc., focuses on non-invasive treatments for basal cell skin cancer using innovative microneedle technology.

Related News